T cells expressing a CD19 specific TRuC eliminated tumor cells in an antigen specific fashion and showed superior therapeutic efficacy in mice bearing CD19+ lymphoma cells as compared to canonical second generation CARs with either CD28 or 4-1BB costimulation (31). This evidence concerns the gene CD19 and lymphoma.